14.99

0.27% +0.04

After Hours: 14.99

Entrada Therapeutics Inc (TRDA)

Overview News Price History Financials Discussions Forecast

Entrada Therapeutics Inc stock is currently priced at $14.99, with a 24-hour trading volume of 103.89K. It has seen a +0.27% increased in the last 24 hours and a +22.67% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $14.83 pivot point. If it approaches the $15.13 resistance level, significant changes may occur.

Previous Close:

$14.95

Open:

$15.34

24h Volume:

103.89K

Market Cap:

$506.05M

Revenue:

Net Income/Loss:

$-6.69M

P/E Ratio:

-5.8101

EPS:

-2.58

Net Cash Flow:

$134.19M

1W Performance:

+4.53%

1M Performance:

+22.67%

6M Performance:

-7.58%

1Y Performance:

+11.20%

1D Range:

$14.78

$15.34

52W Range:

$10.62

$18.44

Entrada Therapeutics Inc Stock (TRDA) Company Profile

Name

Entrada Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

857-520-9158

Address

6 Tide Street, Boston

Employee

Twitter

Next Earnings Date

2024-06-13

Latest SEC Filings

TRDA's Discussions on Twitter

Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-03-23	Initiated	H.C. Wainwright	Buy

Entrada Therapeutics Inc Stock (TRDA) Latest News

Research Associate II, Translational job with Entrada Therapeutics | 2910436 - BioSpace

BioSpace

Entrada Therapeutics director buys $364k in company stock - Investing.com

Investing.com

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ - ForexTV.com

ForexTV.com

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ - WICZ

WICZ

(TRDA) Trading Advice - Stock Traders Daily

Stock Traders Daily

Q2 2024 Earnings Forecast for Entrada Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:TRDA) - MarketBeat

MarketBeat

Entrada Therapeutics Inc Stock (TRDA) Financials Data

Entrada Therapeutics Inc (TRDA) Net Income 2024

TRDA net income (TTM) was -$6.68 million for the quarter ending December 31, 2023, a +92.93% increase year-over-year.

Entrada Therapeutics Inc (TRDA) Cash Flow 2024

TRDA recorded a free cash flow (TTM) of $134.19 million for the quarter ending December 31, 2023, a +238.81% increase year-over-year.

Entrada Therapeutics Inc (TRDA) Earnings per Share 2024

TRDA earnings per share (TTM) was -$0.26 for the quarter ending December 31, 2023, a +91.39% growth year-over-year.

Entrada Therapeutics Inc Stock (TRDA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
KIM PETER S	Director	May 09 '24	Buy	14.25	2,200	31,341	67,412
KIM PETER S	Director	May 08 '24	Buy	14.04	2,276	31,965	65,212
KIM PETER S	Director	Apr 08 '24	Buy	13.57	2,600	35,290	62,936
KIM PETER S	Director	Mar 28 '24	Buy	13.75	1,512	20,794	60,336
KIM PETER S	Director	Mar 26 '24	Buy	13.64	2,750	37,509	58,824
KIM PETER S	Director	Mar 25 '24	Buy	13.36	3,180	42,472	56,074
KIM PETER S	Director	Mar 22 '24	Buy	13.76	3,118	42,901	52,894
KIM PETER S	Director	Mar 21 '24	Buy	13.24	704	9,318	49,776
KIM PETER S	Director	Mar 20 '24	Buy	12.66	1,128	14,281	49,072
KIM PETER S	Director	Mar 19 '24	Buy	12.66	900	11,397	47,944

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.